Defactinib from MedChemExpress

Product Specs
ItemDefactinib
CompanyMedChemExpress
Price $94.00Supplier Page View Company Product Page
Catalog NumberHY-12289
ApplicationsBioactivity, Structure and function analysis, ELISA, SDS-PAGE, Western blotting
Purity99.74%
FormulaC20H21F3N8O3S
Research AreaCancer
TypeChemical
Molecular Weight510.49
Quantity10 mM * 1 mL
Molecule NameDefactinib

Add to Compare List

MedChemExpress

1 Deer Park Drive, Suite F

MONMOUTH JUNCTION, NJ 08852

United States

Phone: US Tel: 609-228-6898
US Fax: 609-228-5909
EU Tel: +4686500910

Email: sales@medchemexpress.com
eu.sales@MedChemExpress.com

Company Profile

Website: medchemexpress.com

(1) Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosisScience AdvancesJanuary 30, 2026Dana K. Mitchell, Kylee Brewster, Li Jiang, Henry Mang, Waylan K. Bessler, Xiaohong Li, Qingbo Lu, Shaomin Qian, Eric York, Sarah K. Morrow, et al.adhere overnight. Cells were then treated with increasing concentrations of defactinib (MedChemExpress, HY-12289) or FAK PROTAC Degrader 1 (MedChemExpress, HY-119932). Cell viability was assessed using the CellTiter-Glo

(2) RhoE downregulation leads to enhanced cholesterol biosynthesis and sorafenib resistance in hepatocellular carcinomaJournal of Biological ChemistryDecember 1, 2025Jingxiu Feng, Ling Ye, Changyuan Chen, Yiyi Zhu, Rumin Liu, Haolong Yu, Lijun Lu, Ke Gong, Wenhua Liachieved, characterized by a significantly increased IC50 compared to parental HepG2 cells. Defactinib (HY-12289), PF-573228 (HY-10461), sorafenib (HY-10201), lovastatin (HY-N0504), and simvastatin (HY-17502) were

(3) Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRCbioRxivAugust 5, 2025Salvador Alonso, Kevan Chu, Marie J Parsons, Elizabeth Granowsky, Himari Gunasinghe, Jinru Shia, Rona Yaeger, Lukas E. DowGSK8612 (MedChemExpress HY-111941), alpelisib (MedChemExpress, HY-15244), defactinib (MedChemExpress HY-12289 ), TPCA-1 (MedChemExpress HY-10074), pexidartinib (MedChemExpress HY-16749), SP600125 (MedChemExpress

(4) Irisin regulates integrin αvβ5/FAK/ERK to inhibit neutrophil extracellular traps formation and reduce pancreatic beta-cells pyroptosis in type 2 diabetes mellitusDiabetol Metab SyndrJuly 18, 2025Anjun Tan, Tianrong Li, Jingjing Yang, Xiaolu Li, Wenqin Li, Jinwen Yu+ PMA and Cilengitide + PMA group, cells were pre-treated with 1 µM Defactinib (FAK inhibitor, MCE, HY-12289) or 1 µM Cilengitide (αV/β5 inhibitor, MCE, HY-16141), respectively, for 30 min, followed by 1 mM PMA

(5) Melatonin attenuates Helicobacter pylori-mediated cholangiocarcinoma-associated fibroblast activation via modulating integrin/FAK signaling pathwaySci RepMay 6, 2025Sirinapha Klungsaeng, Nuttanan Hongsrichan, Apisit Chaidee, Kitti Intuyod, Porntip Pinlaor, Sittiruk Roytrakul, Kulthida Vaeteewoottacharn, Sawanya Charoenlappanit, Rungtiwa Dangtakot, Narumon Mahaamnad, et al.part of the Transwell insert and FBS-free DMEM or melatonin (500 and 2,000 µM) or defactinib (10 µM) (HY12289; MedChemExpress, USA), a novel FAK inhibitor, was added to the upper part of the Transwell insert. After

(6) Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancerThe EMBO JournalJanuary 21, 2025Shuang Li, Meng Sun, Yun Cui, Dongyang Guo, Feng Yang, Qiang Sun, Yinuo Ding, Mengjie Li, Yiman Liu, Guangshuo Ou, et al.proteins used in cell treatment including Erlotinib (HY-50896, MCE), U0126 (HY-12031A, MCE), Defactinib (HY-12289, MCE), Ephrin A1-Fc protein (6417-A1, R&D Systems). Human specimens Clinical samples for tissue array analysis

(7) CSE1L in enhancing the effect of defactinib on gastric cancer cells via the inhibition of FAK phosphorylationTranslational cancer researchDecember 31, 2024He X, Wang Y, Zhang Y, Sahu A, Almhanna K, Liu Y.being directly proportional to the number of viable cells and the formazan product formed. Defactinib (HY-12289; MedChemExpress, Monmouth Junction, NJ, USA) was used in accordance with the guidelines provided by

(8) Exosomal CTHRC1 from cancer-associated fibroblasts facilitates endometrial cancer progression via ITGB3/FAK signaling pathwayHeliyonAugust 30, 2024Yiding Bian, Xinwen Chang, Xiang Hu, Bilan Li, Yunfeng Song, Zhiyi Hu, Kai Wang, Xiaoping Wan, Wen Lu105 (100 μL) AN3CA cells. Exo-CTHRC1 (10 mg/kg) alone or in combination with Defactinib (25 mg/kg, HY-12289, MedChemExpress, Shanghai, China) were injected intraperitoneally every five days, exo-NC was used as

(9) Increased expression of OPN contributes to idiopathic pulmonary fibrosis and indicates a poor prognosisJournal of translational medicineSeptember 19, 2023Ji J, Zheng S, Liu Y, Xie T, Zhu X, Nie Y, Shen Y, Han X.inhibitor defactinib (a specific FAK phosphorylation inhibitor) were purchased from Medchemexpress (no. HY-12289). Mouse and human recombinant OPN were purchased from R&D Systems (no. 441-OP-050, no. 1433-OP-050).

(10) EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activationNature communicationsMay 10, 2022Zhang L, Qu J, Qi Y, Duan Y, Huang YW, Zhou Z, Li P, Yao J, Huang B, Zhang S, et al.(#17737), and VS-4718 (#17668) were purchased from Cayman Chemical. GSK126 (#HY-13470) and VS-6063 (#HY-12289) were purchased from MedChemExpress. EPZ-6438 (#1463254-99-8) were purchased from TargetMol. TGFβ (#4342-5)

(11) Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of boneCell death & diseaseSeptember 23, 2021He Y, Cheng D, Lian C, Liu Y, Luo W, Wang Y, Ma C, Wu Q, Tian P, He D, et al.this study. The FAK inhibitor Defactinib for in vitro assay (2 μM) was obtained from MedChemExpress (HY-12289). Osteoclastogenesis assays Osteoclastogenesis was conducted with bone marrow harvested from 4- to

(12) Defactinib attenuates osteoarthritis by inhibiting positive feedback loop between H-type vessels and MSCs in subchondral boneJournal of orthopaedic translationSeptember 1, 2020Hu Y, Wu H, Xu T, Wang Y, Qin H, Yao Z, Chen P, Xie Y, Ji Z, Yang K, et al.ACLT mice (solvents of defactinib), and defactinib-treated ACLT mice (n = 10 per group). Defactinib (HY-12289, MCE) was administered intraperitoneally weekly (25 mg/kg) [25]. The 30 mice were euthanized one month

(13) Collagen triple helix repeat containing 1 promotes endometrial cancer cell migration by activating the focal adhesion kinase signaling pathwayExperimental and Therapeutic MedicineJune 4, 2020Xiang Hu, Yiding Bian, Xiaoli Wen, Mengfei Wang, Yiran Li, Xiaoping Wanprotein CTHRC1 (100 µg/ml; Abcam), CTHRC1 with the FAK signaling inhibitor defactinib (1 µM; cat. no. HY-12289; MedChemExpress) or recombinant protein CTHRC1 (100 µg/ml) with the FAK signaling inhibitor Y15 (1 µM;

(14) Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancerJournal of experimental & clinical cancer research : CRJuly 28, 2018Shen J, Cao B, Wang Y, Ma C, Zeng Z, Liu L, Li X, Tao D, Gong J, Xie D.phosphorylation in YAP-induced FA formation, a novel FAK inhibitor, defactinib (MedChemExpress, Cat. # HY-12289), was used to inhibit FAK Tyr397 phosphorylation in both MCF7-S127A (Fig. 4e) and MDA-MB-231 (Fig. 4f).

(15) A piece of my mind. If these walls could talkJAMAAugust 13, 2014Manning KD.

(16) Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancerJournal of the National Cancer InstituteOctober 2, 2013Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, et al.

Be the First to Write a Review!

Defactinib from MedChemExpress

Description

MedChemExpress

Citations (16)

Reviews

Defactinib from MedChemExpress

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map